Elena H Martnez-Lapiscina

List of Publications by Citations

75 papers	6,148 citations	24 h-index	78 g-index
79 ext. papers	7,393 ext. citations	6.8 avg, IF	5.04 L-index

#	Paper	IF	Citations
75	Primary prevention of cardiovascular disease with a Mediterranean diet. *New England Journal of Medicine*, **2013**, 368, 1279-90	59.2	3041
74	Mediterranean Diet and Age-Related Cognitive Decline: A Randomized Clinical Trial. *JAMA Internal Medicine*, **2015**, 175, 1094-1103	11.5	479
73	Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1318-25	5.5	414
72	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. *Lancet Neurology, The*, **2017**, 16, 797-812	24.1	243
71	The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. *Neurology*, **2016**, 86, 2303-9	6.5	240
70	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. *Lancet Neurology, The*, **2016**, 15, 574-84	24.1	194
69	Virgin olive oil supplementation and long-term cognition: the PREDIMED-NAVARRA randomized, trial. *Journal of Nutrition, Health and Aging*, **2013**, 17, 544-52	5.2	165
68	Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. *Annals of Neurology*, **2014**, 75, 98-107	9.4	163
67	Mediterranean diet and the incidence of cardiovascular disease: a Spanish cohort. *Nutrition, Metabolism and Cardiovascular Diseases*, **2011**, 21, 237-44	4.5	110
66	Dynamics of retinal injury after acute optic neuritis. *Annals of Neurology*, **2015**, 77, 517-28	9.4	107
65	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 8463-8470	11.5	59
64	Structural networks involved in attention and executive functions in multiple sclerosis. *NeuroImage: Clinical*, **2017**, 13, 288-296	5.3	57
63	Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. *Annals of Neurology*, **2019**, 85, 618-629	9.4	51
62	Genotype patterns at CLU, CR1, PICALM and APOE, cognition and Mediterranean diet: the PREDIMED-NAVARRA trial. *Genes and Nutrition*, **2014**, 9, 393	4.3	45
61	Myasthenia gravis: sleep quality, quality of life, and disease severity. *Muscle and Nerve*, **2012**, 46, 174-80	3.4	36
60	Nut consumption and incidence of hypertension: the SUN prospective cohort. *Nutrition, Metabolism and Cardiovascular Diseases*, **2010**, 20, 359-65	4.5	36
59	The visual pathway as a model to understand brain damage in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 1678-85	5	35

58	Colour vision impairment is associated with disease severity in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 1207-16	5	31
57	Monitoring the Course of MS With Optical Coherence Tomography. *Current Treatment Options in Neurology*, **2017**, 19, 15	4.4	28
56	Retinal periphlebitis is associated with multiple sclerosis severity. *Neurology*, **2013**, 81, 877-81	6.5	28
55	Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012. *Journal of Neurology*, **2014**, 261, 759-67	5.5	26
54	Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus. *Neurology: Neuroimmunology and NeuroInflammation*, **2019**, 6,	9.1	26
53	Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. *Therapeutic Advances in Neurological Disorders*, **2016**, 9, 436-40	6.6	25
52	Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. *Journal of Neurology*, **2015**, 262, 2491-7	5.5	24
51	Improved Framework for Tractography Reconstruction of the Optic Radiation. *PLoS ONE*, **2015**, 10, e0137064	3.7	24
50	The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. *BMC Research Notes*, **2014**, 7, 910	2.3	24
49	Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. *JAMA Neurology*, **2018**, 75, 1246-1255	17.2	24
48	Dynamics and heterogeneity of brain damage in multiple sclerosis. *PLoS Computational Biology*, **2017**, 13, e1005757	5	23
47	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2019**, 5, 2055217319871582	2	22
46	Knowledge retrieval from PubMed abstracts and electronic medical records with the Multiple Sclerosis Ontology. *PLoS ONE*, **2015**, 10, e0116718	3.7	22
45	Cortico-juxtacortical involvement increases risk of epileptic seizures in multiple sclerosis. *Acta Neurologica Scandinavica*, **2013**, 128, 24-31	3.8	20
44	Retrograde retinal damage after acute optic tract lesion in MS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 824-6	5.5	19
43	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. *Neurology*, **2021**, 97, 68-79	6.5	19
42	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. *Multiple Sclerosis Journal*, **2016**, 22, 564-8	5	18
41	Associations of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis, a systematic review and meta-analysis. *Journal of the Neurological Sciences*, **2020**, 411, 116668	3.2	17

40	Early retinal atrophy predicts long-term visual impairment after acute optic neuritis. *Multiple Sclerosis Journal*, **2018**, 24, 1196-1204	5	17
39	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. *Brain*, **2020**, 143, 1127-1142	11.2	17
38	Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis. *NeuroImage: Clinical*, **2018**, 20, 161-168	5.3	14
37	Visual field impairment captures disease burden in multiple sclerosis. *Journal of Neurology*, **2016**, 263, 695-702	5.5	13
36	Predictors of vision impairment in Multiple Sclerosis. *PLoS ONE*, **2018**, 13, e0195856	3.7	13
35	Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors. *Multiple Sclerosis and Related Disorders*, **2020**, 38, 101483	4	13
34	Walking function in clinical monitoring of multiple sclerosis by telemedicine. *Journal of Neurology*, **2015**, 262, 1706-13	5.5	12
33	Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 9-14	5.5	10
32	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. *Multiple Sclerosis and Related Disorders*, **2019**, 28, 230-234	4	10
31	Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. *Neurology*, **2020**, 94, e1950-e1960	6.5	10
30	Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. *JAMA Neurology*, **2020**, 77, 234-244	17.2	8
29	The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis. *Journal of Neuro-Ophthalmology*, **2018**, 38, 494-501	2.6	8
28	Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 1234-5	5	7
27	Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients. *NeuroImage: Clinical*, **2021**, 30, 102653	5.3	7
26	Impairment of decision-making in multiple sclerosis: A neuroeconomic approach. *Multiple Sclerosis Journal*, **2017**, 23, 1762-1771	5	6
25	Precision medicine for multiple sclerosis: an update of the available biomarkers and their use in therapeutic decision making. *Expert Review of Precision Medicine and Drug Development*, **2017**, 2, 345-361	1.6	6
24	The analysis of semantic networks in multiple sclerosis identifies preferential damage of long-range connectivity. *Multiple Sclerosis and Related Disorders*, **2015**, 4, 387-394	4	6
23	Spanish validation of the telephone assessed Expanded Disability Status Scale and Patient Determined Disease Steps in people with multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2019**, 27, 333-339	4	6

22	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). *BMJ Open*, **2020**, 10, e035397	3	5
21	Retinal Optical Coherence Tomography in Neuromyelitis Optica. *Neurology: Neuroimmunology and NeuroInflammation*, **2021**, 8,	9.1	5
20	Remyelination: a good neuroprotective strategy for preventing axonal degeneration?. *Brain*, **2019**, 142, 233-236	11.2	3
19	Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon. *Journal of the Neurological Sciences*, **2018**, 387, 60-69	3.2	3
18	Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine. *Therapeutic Advances in Neurological Disorders*, **2018**, 11, 1756286418780007	6.6	3
17	Healthy diet, depression and quality of life: A narrative review of biological mechanisms and primary prevention opportunities. *World Journal of Psychiatry*, **2021**, 11, 997-1016	3	3
16	Impact of Cognitive Reserve and Structural Connectivity on Cognitive Performance in Multiple Sclerosis. *Frontiers in Neurology*, **2020**, 11, 581700	4.1	3
15	Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. *Scientific Reports*, **2020**, 10, 13333	4.9	3
14	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. *Multiple Sclerosis Journal*, **2021**, 27, 1706-1716	5	3
13	A Healthy Diet for Your Heart and Your Brain **2018**, 169-197		3
12	In Vivo Molecular Changes in the Retina of Patients With Multiple Sclerosis **2021**, 62, 11		2
11	Phenytoin for neuroprotection. *Lancet Neurology, The*, **2016**, 15, 901-902	24.1	2
10	Reporting of R2 Statistics for Mixed-Effects Regression Models-Reply. *JAMA Neurology*, **2019**, 76, 507-508	17.2	1
9	Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis. *Journal of Personalized Medicine*, **2021**, 11,	3.6	1
8	Lipoma: An Overview. *Tumors of the Central Nervous System*, **2014**, 223-229		1
7	The popularity of neurology in Spain: An analysis of specialty selection. *Neurología*, **2020**, 35, 543-550	1.4	1
6	Retinal inflammation in multiple sclerosis revealed by optical coherence tomography and ophthalmoscopy176-183		
5	Reply to the letter to the editor by Lucena Romero et al. on the article Epileptic seizure and lipoma of corpus callosum: Cause or incidental finding *Neurología (English Edition)*, **2012**, 27, 58-59	0.4	

4 Epileptic seizure and lipoma of corpus callosum: cause or incidental finding. *Neurología (English Edition)*, **2010**, 25, 331-332 0.4

3 Trans Neuronal Retrograde Degeneration to OCT in Central Nervous System Diseases **2020**, 365-374

2 Drug Trials in Neuroprotection **2016**, 171-184

1 Trans Neuronal Retrograde Degeneration to OCT in Central Nervous System Diseases **2016**, 205-214